A proteomic landscape of diffuse-type gastric cancer

The diffuse-type gastric cancer (DGC) is a subtype of gastric cancer with the worst prognosis and few treatment options. Here we present a dataset from 84 DGC patients, composed of a proteome of 11,340 gene products and mutation information of 274 cancer driver genes covering paired tumor and nearby...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Sai, Xia, Xia, Ding, Chen, Zhen, Bei, Zhou, Quan, Feng, Jinwen, Yuan, Jiajia, Chen, Rui, Li, Yumei, Ge, Zhongqi, Ji, Jiafu, Zhang, Lianhai, Wang, Jiayuan, Li, Zhongwu, Lai, Yumei, Hu, Ying, Li, Yanyan, Li, Yilin, Gao, Jing, Chen, Lin, Xu, Jianming, Zhang, Chunchao, Jung, Sung Yun, Choi, Jong Min, Jain, Antrix, Liu, Mingwei, Song, Lei, Liu, Wanlin, Guo, Gaigai, Gong, Tongqing, Huang, Yin, Qiu, Yang, Huang, Wenwen, Shi, Tieliu, Zhu, Weimin, Wang, Yi, He, Fuchu, Shen, Lin, Qin, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843664/
https://www.ncbi.nlm.nih.gov/pubmed/29520031
http://dx.doi.org/10.1038/s41467-018-03121-2
Descripción
Sumario:The diffuse-type gastric cancer (DGC) is a subtype of gastric cancer with the worst prognosis and few treatment options. Here we present a dataset from 84 DGC patients, composed of a proteome of 11,340 gene products and mutation information of 274 cancer driver genes covering paired tumor and nearby tissue. DGC can be classified into three subtypes (PX1–3) based on the altered proteome alone. PX1 and PX2 exhibit dysregulation in the cell cycle and PX2 features an additional EMT process; PX3 is enriched in immune response proteins, has the worst survival, and is insensitive to chemotherapy. Data analysis revealed four major vulnerabilities in DGC that may be targeted for treatment, and allowed the nomination of potential immunotherapy targets for DGC patients, particularly for those in PX3. This dataset provides a rich resource for information and knowledge mining toward altered signaling pathways in DGC and demonstrates the benefit of proteomic analysis in cancer molecular subtyping.

Ejemplares similares